OBJECTIVES: In the Netherlands, people at risk for chronic Q fever were vaccinated against Coxiella burnetii with the inactivated whole cell vaccine Q-vax®. We aimed to measure the immune responses to C. burnetii six and twelve months after vaccination in this relevant population. METHODS: In 260 vaccinees, antibody responses were assessed by immunofluorescence assay (IFA), complement fixation test and ELISA. The cellular immune responses were assessed by measuring C. burnetii-specific interferon (IFN)-γ production in blood. Serological results of 200 individuals with past Q fever were used for comparison. RESULTS: At six months, 46% of vaccinees showed low IFA antibody titres and 67% had a positive IFN-γ assay; At twelve months, both were 60%. In contrast, individuals with a past Q fever were seropositive in 99.5% at six and twelve months, with relatively higher IFA titres. Interestingly, vaccinees with positive IFN-γ assay pre-vaccination, showed a higher seroconversion rate than IFN-γ negative vaccinees: 74% vs. 41% (p < 0.001). CONCLUSIONS: The immune response after Q-vax® vaccination is lower and restricted to a smaller proportion than found after past Q fever and than previously described after vaccination, suggesting decreased vaccine immunogenicity in this high-risk population. A positive IFN-γ assay before vaccination in seronegative vaccinees likely points to pre-existing immunity resulting in boosting by vaccination.
OBJECTIVES: In the Netherlands, people at risk for chronic Q fever were vaccinated against Coxiella burnetii with the inactivated whole cell vaccine Q-vax®. We aimed to measure the immune responses to C. burnetii six and twelve months after vaccination in this relevant population. METHODS: In 260 vaccinees, antibody responses were assessed by immunofluorescence assay (IFA), complement fixation test and ELISA. The cellular immune responses were assessed by measuring C. burnetii-specific interferon (IFN)-γ production in blood. Serological results of 200 individuals with past Q fever were used for comparison. RESULTS: At six months, 46% of vaccinees showed low IFA antibody titres and 67% had a positive IFN-γ assay; At twelve months, both were 60%. In contrast, individuals with a past Q fever were seropositive in 99.5% at six and twelve months, with relatively higher IFA titres. Interestingly, vaccinees with positive IFN-γ assay pre-vaccination, showed a higher seroconversion rate than IFN-γ negative vaccinees: 74% vs. 41% (p < 0.001). CONCLUSIONS: The immune response after Q-vax® vaccination is lower and restricted to a smaller proportion than found after past Q fever and than previously described after vaccination, suggesting decreased vaccine immunogenicity in this high-risk population. A positive IFN-γ assay before vaccination in seronegative vaccinees likely points to pre-existing immunity resulting in boosting by vaccination.
Authors: Teske Schoffelen; Joshua S Self; Kelly A Fitzpatrick; Mihai G Netea; Marcel van Deuren; Leo A B Joosten; Gilbert J Kersh Journal: Diagn Microbiol Infect Dis Date: 2014-12-30 Impact factor: 2.803
Authors: Susan Raju Paul; Anja Scholzen; Ghazel Mukhtar; Stephanie Wilkinson; Peter Hobson; Richard K Dzeng; Jennifer Evans; Jennifer Robson; Rowland Cobbold; Stephen Graves; Mark C Poznansky; Anja Garritsen; Ann E Sluder Journal: Front Immunol Date: 2022-06-23 Impact factor: 8.786
Authors: Patricia E Vermeer-de Bondt; Teske Schoffelen; Ann M Vanrolleghem; Leslie D Isken; Marcel van Deuren; Miriam C J M Sturkenboom; Aura Timen Journal: PLoS One Date: 2015-04-24 Impact factor: 3.240
Authors: Emily Sellens; Jacqueline M Norris; Navneet K Dhand; Jane Heller; Lynne Hayes; Heather F Gidding; Harold Willaby; Nicholas Wood; Katrina L Bosward Journal: PLoS One Date: 2018-06-01 Impact factor: 3.240
Authors: Anja Scholzen; Margot de Vries; Hans-Peter Duerr; Hendrik-Jan Roest; Ann E Sluder; Mark C Poznansky; Milou L C E Kouwijzer; Anja Garritsen Journal: Front Immunol Date: 2021-07-28 Impact factor: 7.561
Authors: Teske Schoffelen; Gijs J M Limonard; Chantal P Bleeker-Rovers; John J M Bouwman; Jos W M van der Meer; Marrigje Nabuurs-Franssen; Tom Sprong; Marcel van Deuren Journal: PLoS One Date: 2014-08-01 Impact factor: 3.240
Authors: P M Reeves; S Raju Paul; L Baeten; S E Korek; Y Yi; J Hess; D Sobell; A Scholzen; A Garritsen; A S De Groot; L Moise; T Brauns; R Bowen; A E Sluder; M C Poznansky Journal: Sci Rep Date: 2020-08-07 Impact factor: 4.379